All In Biotech

Drug Trial Radar · NCT06863272

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jul 3, 2025

Primary completion

Oct 1, 2031

Study completion Oct 1, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.

Conditions

  • Castration-Resistant Prostatic Cancer
  • Metastasis

Interventions

  • DocetaxelDrug

    Administered via Intravenous (IV) infusion at a specified dose on specified days

  • Ifinatamab DeruxtecanDrug

    Administered via IV infusion at a specified dose on specified days

  • OpevesostatDrug

    Administered orally at a specified dose on specified days

  • AbirateroneDrug

    Administered orally at a specified dose on specified days

  • EnzalutamideDrug

    Administered orally at a specified dose on specified days

  • Rescue MedicationDrug

    Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms OnlyTime frame: Up to approximately 21 days
  2. Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 54 months
  3. Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 24 months
  4. Efficacy Phase: Prostate-Specific Antigen (PSA) response rateTime frame: Up to approximately 54 months
  5. Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms OnlyTime frame: Up to approximately 21 days
  6. Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms OnlyTime frame: Up to approximately 21 days
  7. Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms OnlyTime frame: Up to approximately 21 days

Locations

82 sites in 19 countries. Site status is shown where the registry gives one.

  • UCLA Hematology & Oncology ( Site 0003)

    Los Angeles, California · Recruiting

  • University of California-Irvine Medical Center ( Site 0016)

    Orange, California · Recruiting

  • UCSF Medical Center at Mission Bay ( Site 0034)

    San Francisco, California · Recruiting

  • MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)

    Washington D.C., District of Columbia · Recruiting

  • University of Michigan ( Site 0021)

    Ann Arbor, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0006)

    New York, New York · Recruiting

  • UPMC Hillman Cancer Center ( Site 0014)

    Pittsburgh, Pennsylvania · Recruiting

  • The West Clinic, PLLC dba West Cancer Center ( Site 0005)

    Germantown, Tennessee · Recruiting

  • Fred Hutchinson Cancer Center ( Site 0013)

    Seattle, Washington · Recruiting

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)

    La Rioja, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0202)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)

    Macquarie University, New South Wales, Australia · Recruiting

  • IPITEC ( Site 0275)

    São Paulo, Brazil · Recruiting

  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)

    São Paulo, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 0271)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Moinhos de Vento ( Site 0278)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)

    Bragança Paulista, São Paulo, Brazil · Recruiting

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Hospital Alemao Oswaldo Cruz ( Site 0279)

    São Paulo, São Paulo, Brazil · Recruiting

  • BC Cancer - Vancouver Center ( Site 0103)

    Vancouver, British Columbia, Canada · Recruiting

  • Sunnybrook Research Institute ( Site 0109)

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre ( Site 0102)

    Toronto, Ontario, Canada · Recruiting

  • Jewish General Hospital ( Site 0108)

    Montreal, Quebec, Canada · Recruiting

  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)

    Sherbrooke, Quebec, Canada · Recruiting

  • Clinica Universidad Catolica del Maule ( Site 0236)

    Talca, Maule Region, Chile · Recruiting

  • Fundación Arturo López Pérez ( Site 0232)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Oncología de Precisión ( Site 0241)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0231)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • ONCOCENTRO APYS ( Site 0234)

    Viña del Mar, Valparaiso, Chile · Recruiting

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)

    Bordeaux, Gironde, France · Recruiting

  • Centre Oscar Lambret ( Site 0495)

    Lille, Nord, France · Recruiting

  • Institut De Cancerologie De L Ouest ( Site 0494)

    Saint-Herblain, Pays de la Loire Region, France · Recruiting

  • Centre Hospitalier de la Cote Basque ( Site 0496)

    Bayonne, Pyrenees-Atlantiques, France · Recruiting

  • centre hospitalier lyon sud ( Site 0497)

    Pierre-Bénite, Rhone, France · Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)

    Hamburg, Germany · Recruiting

  • NCT ( Site 0528)

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Ulm. ( Site 0530)

    Ulm, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Jena ( Site 0525)

    Jena, Thuringia, Germany · Recruiting

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.